An interventional study of Exercise training in HIV Infections, sponsored by Instituto Nacional de Cardiologia de Laranjeiras. Recruiting at 1 site in Brazil. Open to participants aged 30 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Instituto Nacional de Cardiologia de Laranjeiras · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in HIV Infections with a site in Brazil — 12 open to participants now, 17 under way, 5 of them phase 3. HIV Infections · Brazil.
Among the 142 studies in HIV Infections with a site in Brazil, this one is the 88th largest by planned enrollment of the 116 interventional ones that give a count, is one of 3 that started in 2024, is one of 16 with no phase, reaches primary completion later than 7 of the 16 other live ones, and was the 121st registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →12 of the 142 studies in HIV Infections with a site in Brazil are open now. Recruiting first, the newest first:
Oswaldo Cruz Foundation · Sites in Brazil
Ages 18+ · Men only · Healthy volunteers
Oswaldo Cruz Foundation · Sites in Brazil
Ages 18+ · Healthy volunteers
Oswaldo Cruz Foundation · Sites in Brazil
Ages 15+ · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in Brazil, United States, Peru
Ages 18–70
Code Pharma · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 30 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 33 · Phase 3 45 · Phase 4 21
First in 1999; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 63 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 255 across the 116 interventional studies, 229 across the 22 observational. Of the 119 that completed or were terminated, 61 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 142 have an industry lead sponsor. The 10 most frequent:
Instituto Nacional de Cardiologia de Laranjeiras is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Instituto Nacional de Cardiologia de Laranjeiras has 1 study filed under HIV Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in HIV Infections with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07584122Oswaldo Cruz FoundationImproving Access to PrEP (HIV Prevention Medication) for People in Underserved Areas of Rio de Janeiro | 2026-12 |
| NCT04512456Instituto Nacional de Cardiologia de LaranjeirasCardiovascular Responses to Exercise in People Living With HIV/AIDS: Effects of Exercise Training | 2026-12-31 |
| NCT07500415Oswaldo Cruz FoundationDoxi-Rio: Study on the Use of Doxycycline to Prevent Sexually Transmitted Infections in Rio de Janeiro | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 142 studies in HIV Infections with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients living with HIV (PLWHIV) have compromised muscle metaboreflex, which can cause exercise intolerance. This randomized controlled clinical trial will verify the effects of regular exercise on autonomic and hemodynamic responses to muscle ergoreflex activation in these patients. PLWHIV without regular physical exercise will be randomly assigned into an exercise training or a control group. The exercise training group will undergo regular physical exercise during 12 weeks (60-min session performed 3 times/wk with moderate intensity), while the control group will keep inactive. Another group consisted of inactive HIV-uninfected group will be included. The primary endpoints will be blood pressure and autonomic markers in response to the Stroop Color-Word Test and the activation of muscle ergoreflex, by means of the post-exercise circulatory arrest (PECA), which will be performed with and without the topical application of a capsaicin-based analgesic balm. Secondary endpoints will include heart rate, peripheral vascular resistance, stroke volume, cardiac output, blood lactate concentration, anthropometrics, and handgrip strength. The active and inactive PLWHIV groups will be evaluated before and after the exercise training, while the healthy group only at baseline.
HIV-infection is associated to a reduced maximal cardiac output and blunted pressor reflex response to static handgrip exercise, which are suggestive of impaired ergoreflex activation. An abnormal ergoreflex activation may lead to exercise intolerance and increases in cardiovascular risk. Despite the importance of therapeutic strategies in reducing the cardiovascular risk among patients living with HIV, exercise-related effects on ergoreflex sensitivity in these population have not been previously investigated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Exercise training
Behavioral: Exercise training
No intervention.
No intervention.
Exercise training performed during 12 weeks, 3 sessions per week of 60 minutes of strength and aerobic exercises.
Change from Baseline Blood Pressure at 3 months
Blood pressure will be assessed by a digital sphygmomanometer.
Time frame: Baseline and 3 months of follow-up
Change from Baseline Heart Rate Variability at 3 months
Heart rate variability will be assessed by a heart rate monitor.
Time frame: Baseline and 3 months of follow-up
Change from Baseline Heart Rate at 3 months
Heart rate will be evaluated beat-to-beat by means of a heart rate monitor.
Time frame: Baseline and 3 months of follow-up
Change from Baseline Peripheral Vascular Resistance at 3 months
Peripheral Vascular Resistance will be evaluated by photpletismography.
Time frame: Baseline and 3 months of follow-up
Change from Baseline Stroke Volume at 3 months
Stroke Volume will be evaluated by photoplethysmography.
Time frame: Baseline and 3 months of follow-up
Change from Baseline Cardiac Output at 3 months
Cardiac Output will be evaluated by photoplethysmography.
Time frame: Baseline and 3 months of follow-up
Change from Baseline Blood Lactate at 3 months
Blood Lactate will be determined by the YSL 2700 analyzer.
Time frame: Baseline and 3 months of follow-up.
Change from Baseline Anthropometric markers at 3 months
Anthropometric markers will be determined by a digital scale and wall-mounted stadiometer.
Time frame: Baseline and 3 months of follow-up.
Change from Baseline handgrip maximal voluntary contraction at 3 months
Handgrip maximal voluntary contraction will be assessed using a hydraulic handgrip dynamometer.
Time frame: Baseline and 3 months of follow-up.
Plan to share: No
Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.
Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 28 months is close to that.
Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Nacional de Cardiologia de Laranjeiras